travellinglight/iStock via Getty Images
- Cassava Sciences (NASDAQ:SAVA) traded higher on Wednesday after announcing Phase 3 data to indicate that its Alzheimer’s candidate, simufilam, is not linked to a common group of side effects associated with FDA-approved Alzheimer’s medications.
- Citing an independent analysis of magnetic resonance imaging (MRI) brain data from a Phase 3 trial for oral simufilam, the company said that its drug was not associated with the safety issue at Week 40.
- The safety concerns it cited are MRI imaging changes called treatment-emergent amyloid-related imaging abnormalities (ARIA), such as edema and brain bleeds.
- ARIAs are often linked to FDA-approved amyloid-targeting Alzheimer’s drugs such as Leqembi, developed by Biogen (BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY). Simufilam, Cassava’s (SAVA) lead asset targets filamin A, a protein linked to Alzheimer’s pathogenesis.
- The company expects to report final MRI data after the 76-week trial for patients with mild-to-moderate Alzheimer’s concludes.
More on Cassava Sciences
- Cassava Sciences' Integrity Under Scrutiny Following CUNY Misconduct Claims
- Cassava Sciences: Update Following Leaked CUNY Report, Fundamentals Remain Unchanged
- Cassava Sciences: Unconvincing Open Label Studies, Upcoming Phase 3, Risky AD Bet
- Cassava stock falls 15% in wake of negative report on CUNY researcher
- Cassava falls 38% on investigation into simufilam data manipulation (updated)